Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 463-469

  Sullivan, Patrick S ^a,e   Do, Ann N ^a   Ellenberger, Dennis ^b   Pau, Chou Pong ^b   Paul, Sindy ^c   Robbins, Ken ^b   Kalish, Marcia ^b   Storck, Courtland ^d   Schable, Charles A ^b   Wise, Harvey ^c   Tetteh, Christopher ^a   Jones, Jeffrey L ^a   McFarland, Jeffrey ^a   Yang, Chunfu ^b   Lal, Renu B ^b   Ward, John W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; PHYLOGENY; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS TYPING;

ADULT; AFRICA; EMIGRATION AND IMMIGRATION; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHYLOGENY; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SEROTYPING; UNITED STATES;

EID: 0034005844     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315254     Document Type: Article

References (41)

1. Hu D, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV: the importance of global surveillance for diagnostics, research, and prevention. JAMA 1996; 275:210-6.
2. Simon F, Mauclere P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998; 4:1032-7.
3. Expert Group of the Joint United Nations Programme on HIV/AIDS. Implications of HIV variability for transmission: scientific and policy issues. AIDS 1997; 11:1-15.
4. Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994; 343:1393-4.
5. Schable C, Zekeng L, Pau CP, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994; 344:1333-4.
6. Gurtler LG, Zekeng L, Tsague JM, et al. HIV-1 subtype O: epidemiology, pathogenesis, diagnosis, and perspectives on the evolution of HIV. Arch Virol 1996; 11:195-202.
7. Zekeng L, Gurtler L, Afane Ze E, et al. Prevalence of HIV-1 subtype O infection in Cameroon: preliminary results. AIDS 1994; 8:1626-8.
8. Pau CP, Hu DJ, Spruill C, et al. Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Transfusion 1996: 36:398-400.
9. Centers for Disease Control and Prevention. HIV/AIDS Surveil Rep 1997; 9:1-43.
10. Castro KG, Lifson AR, White CR, et al. Investigations of AIDS patients with no previously identified risk factors. JAMA 1988; 259:1338-42.
11. Schochetman G, Subbarao S, Kalish ML. Methods for studying genetic variation of the human immunodeficiency virus (HIV). In: Adolph KW, ed. Viral genome methods. New York: CRC Press, 1996:25-41.
12. Brennan CA, Laud JK, Golden A, et al. Serologic and phylogenetic characterization of HIV-1 subtypes in Uganda. AIDS 1997; 11:1823-32.
13. Yang C, Pieniazek D, Owen SM, et al. Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma using highly sensitive and specific generic primers. J Clin Microbiol 1999; 37: 2581-6.
14. Pieniazek D, Yang C, Lal RB. Phylogenetic analysis of gp41 envelope of HIV-1 groups M, N, and O strains provides an alternate region for subtype determination. In: Korber B, Foley B, McCutchan F, et al, eds. Human retrovirus and AIDS. Los Alamos, NM: Los Alamos National Laboratory, 1998:(III)112-7.
15. Irwin KL, Pau CP, Lupo D, et al. Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. J Infect Dis 1997; 176:1629-33.
16. Sullivan PS, Buskin S, Turner J. Use of peptide serology as a screening tool for determining viral subtype among recently HIV-infected persons. In: Program and abstracts of the 14th Annual Conference on Human Retrovirus Testing, Albuquerque, New Mexico, 1999.
17. Laukkanen T, Albert J, Liitsola, K et al. Virtually full-length sequences of HIV type 1 subtype J reference strains. AIDS Res Hum Retroviruses 1999; 15:293-7.
18. Triques K, Bourgeois A, Saragosti S, et al. High diversity of HIV-1 subtype F strains in central Africa. Virology 1999; 259:99-109.
19. Rayfield MA, Sullivan P, Bandea CI, et al. HIV-1 group O virus identified for the first time in the United States. Emerg Infect Dis 1996; 2:209-12.
20. Food and Drug Administration. Memo to all registered blood and plasma establishments: interim recommendations for deferral of donors at increased risk for HIV-1 group O infection. Rockville, MD: FDA, II December 1996.
21. Food and Drug Administration. Memo to investigational new drug application and product license application holders: sensitivity for group O viruses. Rockville, MD: FDA, July 1996.
22. Brodine SK, Mascola JR, Weiss PJ, et al. Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995; 346:1198-9.
23. Sullivan PS, Do AN, Robbins K, et al. Surveillance for variant strains of HIV: subtype G and group O. JAMA 1997; 278:292.
24. Gao F, Yue L, Hille SC, et al. HIV-1 sequence subtype D in the United States. AIDS Res Hum Retroviruses 1994; 10:625-7.
25. Beatrice ST, Oleszko WR, Punsaland A, et al. HIV-2 and non-B subtypes of HIV-1 group M in specimens submitted to the New York City (NYC) Department of Health Retrovirololgy lab from 1993-1997 [abstract 42116]. In: Program and abstracts of the 12th World AIDS Conference (Geneva, Switzerland). Stockholm, Sweden: International AIDS Society, 1998.
26. Cheingsong-Popov R, Osmanov S, Pau CP, et al. Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. AIDS Res Hum Retroviruses 1998; 14:311-8.
27. Soto-Ramierez LE, Renjifo B, McLane MF, et al. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 1996; 271:1291-3.
28. Grace JJ, Neilson P, Lewis J, et al. HIV-1 subtype and shedding of cervicovaginal HIV-1 DNA during pregnancy [abstract 13117]. In: Program and abstracts of the 12th World AIDS Conference (Geneva, Switzerland). Stockholm, Sweden: International AIDS Society, 1998.
29. Kaleeby P, Morgan D, Oram J, et al. HIV-1 heterosexual transmission: relationship with HIV-1 subtypes in Uganda [abstract 23357]. In: Program and abstracts of the 12th World AIDS Conference (Geneva, Switzerland). Stockholm, Sweden: International AIDS Society, 1998.
30. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A D. AIDS 1999; 13:901-7.
31. Kanki PJ, Hamel DJ, Sankale JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73.
32. Dunne AL, Crowe SM. Comparison of branched DNA and reverse transcriptase polymerase chain reaction for quantifying six different HIV-1 subtypes in plasma. AIDS 1997; 11:126-7.
33. Loussert-Ajaka I, Descamps D, Simon F, Brun-Vezinet F, Ekwalanga M, Saragosti S. Genetic diversity and HIV detection by polymerase chain reaction. Lancet 1995; 346:912-3.
34. Alaeus A, Lidman K, Sonnerborg A, Albert J. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 1997; 11:859-65.
35. Nkengasong JN, Kalou M, Maurice C, et al. Comparison of NucliSens and Amplicor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Cote d'Ivoire. J Clin Microbiol 1998; 36:2495-8.
36. Oudshoom P, Simons F, Cronin M, Vella S, DeWolf S, Cuypers T. Quantitation of HIV-1 RNA by the NucliSens HIV-1 QT assay [abstract 312]. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago, IL). Alexandria, VA: Infectious Diseases Society of America, 1998.
37. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1998; 14:157-62.
38. Apetrei C, Loussert-Ajaka I, Descamps D, et al. Lack of screening test sensitivity during HIV-1 non-B subtype seroconversions. AIDS 1996; 10: F57-60.
39. Girarg M, Yue L, Barre-Sinoussi F, et al. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B -derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J Virol 1996; 70:8229-33.
40. Hu DJ, Buvé A, Baggs J, van der Groen G, Dondero TJ. What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS 1999; 13:873-81.
41. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definitions for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.